Our VHH Antibody Platform built on FC8™

At Cortalix, every VHH antibody program is built on a single foundation: our proprietary FC8TM scaffold framework. The framework is humanized, thermally stable, and designed for favourable developability. In silico modelling predicts a low intrinsic aggregation propensity of the framework itself, while the aggregation behaviour of each final VHH is also influenced by its unique CDR sequences.

The FC8™ framework was engineered to provide an excellent developability foundation for synthetic VHH discovery. Its favourable biophysical properties include high thermal stability, efficient refolding after thermal stress and a low intrinsic aggregation propensity predicted by in silico modelling.
The final developability profile of any selected VHH is determined by the combination of the FC8TM framework and its unique CDRs, which contribute substantially to the molecule’s physicochemical behaviour. Therefore, aggregation propensity and other developability characteristics are ultimately evaluated for each lead candidate individually.

From that foundation, we’ve built a suite of platforms spanning discovery, multispecific engineering, half-life extension, and CAR-T design, each modular, and each ready to plug into the next.

Discovery Platform

VHH discovery via FC8TM: ribosomal display, screening a functional diversity of up to 1014 variants, transitioning seamlessly into phage display for precise hit enrichment. For the most complex or conformational targets, we complement this with immune library discovery.

• Up to 1014 functional diversity via ribosomal display
• Animal-free, fast, clinical-ready by design
• Immune libraries available for complex or conformational targets

Our platform for multivalent and multispecific VHH antibody constructs. By linking two, three, or more VHH domains with carefully selected linkers, we create bispecific, multi-epitope, or valency-tuned constructs, without sacrificing the stability and solubility of monovalent VHHs.

• Bi- and tri-specific constructs
• Superior stability compared to scFv or Fab fragments
• Applications in oncology,  targeted therapeutics, radiopharmaceuticals, and inflammation

AlbuFlexTM Platform

Our albumin-binding VHH antibody platform, designed to exploit the natural half-life extension and biodistribution properties of serum albumin, giving you tunable control over the pharmacokinetics of your VHH therapeutic.

• Tunable half-life extension through modular albumin-binding design
• Integrates directly into the MultiDomeTM platform
• Applications in oncology, targeted therapeutics, radiopharmaceuticals, and inflammatory disease

CARVexTM Platform

• Optimized tonic signaling (PCP-tuned) to reduce T-cell exhaustion
• Monospecific, bispecific, or tandem NanoCAR designs
• Superior biophysical properties compared to scFv-based CARs

Let’s Discuss Your Project

Not sure which platform fits your target or application? We’re happy to map out the best route together.